WEKO3
アイテム
Prediction of efficacy of lamivudine therapy for chronic type B liver diseases : studies based on changes in HBV-DNA amount and YMDD motif
https://iwate-pu.repo.nii.ac.jp/records/1737
https://iwate-pu.repo.nii.ac.jp/records/1737364e25b2-be1b-47de-ae9b-1762447fd4df
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00004764796.pdf (679.6 kB)
|
|
| Item type | [ELS]紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-12-27 | |||||
| タイトル | ||||||
| タイトル | Prediction of efficacy of lamivudine therapy for chronic type B liver diseases : studies based on changes in HBV-DNA amount and YMDD motif | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | lamivudine | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | YMDD motif | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | HBV-DNA | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | breakthrough hepatitis | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 雑誌書誌ID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA11373559 | |||||
| 著者 |
Ishikawa, Kazuyoshi
× Ishikawa, Kazuyoshi× Nakakarumai, Chihoko× Matsumoto, Chie× Ooe, Sayaka× Isobe, Naoko |
|||||
| 著者所属(日) | ||||||
| Faculty of Nursing, Iwate Prefectural University | ||||||
| 著者所属(日) | ||||||
| Iwate Seiwa Hospital | ||||||
| 著者所属(日) | ||||||
| Faculty of Nursing, Iwate Prefectural University | ||||||
| 著者所属(日) | ||||||
| Faculty of Nursing, Iwate Prefectural University | ||||||
| 著者所属(日) | ||||||
| Iwate Health Service Association | ||||||
| 記事種別(日) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 原著 | |||||
| 記事種別(英) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Original Article | |||||
| 抄録(日) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Lamivudine 100mg/日を経口投与し,1年以上の観察が可能であったB型慢性肝炎4例および非代償性肝硬変1例の計5例を対象とし,変異ウイルスの出現頻度および変異のパターンと臨床経過の関連について検討した.対象の内訳は全例男性,平均年齢は55.0±6.9歳(47～65歳),平均観察期間は39.0±15.5ヵ月である.治療前のHBV-DNA量は5.8～6.9LGE/mL,ALT値は33～471IU/Lに分布し,HBe抗原陽性は肝硬変の1例のみで,genotypeは全例Cであった.Lamivudine投与開始前のYMDD motifは5例中4例が"YMDD"のwild typeであったが,少量間欠投与から継続して投与を行った1例は"YVDD"のmutant typeであった.Lamivudine投与開始前YMDD motifが野生株であった4例中2例(50%)に,投与開始後それぞれ45ヵ月,8ヵ月にYVDD変異株の出現をみた.Lamivudine投与後は,全例1ヵ月以内にHBV-DNA量は3.7LGE/mL未満の検出感度以下に低下し,3ヵ月以内までにALT値も正常化した.YVDD変異株の出現をみた3例中2例は,変異株の出現にもかかわらず,HBV-DNA量が検出感度以下を持続しALT値の正常化や病態の安定をみたが,他の1例はその後の経過中2回,HBV-DNA量の再上昇を伴うALT値の増悪をみている.YMDD motifが野生型を持続した2例はいずれも,HBV-DNA量は検出感度以下を持続しALTも正常値を持続している.YVDD変異株出現例の経過をみると,domain Bの変異の消長とYMDDの変異株の消長との間に時間的位相のずれがみられる場合が有り,このことがLamivudineの治療効果に影響を与えている可能性が示唆された. | |||||
| 抄録(英) | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Lamivudine was orally administered at 100mg/day and was observed for more than 1 year in 5 patients, comprising 4 patients with chronic type B hepatitis and 1 patient with decompensated liver cirrhosis. The relationship between clinical course and frequency of mutant virus emergence and the mutation pattern was investigated in these patients. All 5 patients were male, with a mean age of 55.0±6.9 years and a mean observation period of 39.0±15.5 months. Before the start of lamivudine administration, mean HBV-DNA level was ranging from 5.8 to 6.9LGE/mL and mean ALT level, from 33 to 471IU/L. Only the patient with liver cirrhosis was positive for HBeAg. In all cases, genotype was C. In 4 of the 5 patients, YMDD motif before the start of lamivudine administration was wild-type, but mutant type YVDD was present in 1 patient who had been treated with low-dose intermittent administration of lamivudine prior to changing to the 100mg/day treatment. In 2 of the 4 patients in whom YMDD motif was initially wild type, YVDD variant strains emerged at 45 months and 8 months, respectively, after the start of lamivudine administration. Within 1 month after lamivudine treatment was started, HBV-DNA level in each patient fell below the limit of detection, and within 3 months ALT levels had also normalized. In 2 of 3 patients in whom YVDD mutant strains emerged, HBV-DNA level remained below the limit of detection, ALT was normalized and clinical condition remained stable despite emergence of a variant strain. During the course of observation for the third of these patients, ALT aggravated twice together with an upward rebound in HBV-DNA level. In both patients who continuously showed wild-type YMDD motif, HBV-DNA level remained below the limit of detection and ALT also continued to be normal. Analysis of the course for patients in whom YVDD variants emerged revealed cases with a time-phase discrepancy between fluctuations in variants in domain B and fluctuations in YMDD variants. This suggests the possibility that this discrepancy influences the therapeutic effects of lamivudine. | |||||
| 書誌情報 |
ja : 岩手県立大学看護学部紀要 en : Journal of the Faculty of Nursing, Iwate Prefectural University 巻 9, p. 13-20, 発行日 2007-01-01 |
|||||
| 表示順 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 4 | |||||
| アクセション番号 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | KJ00004764796 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 13449745 | |||||
